At Frontage, we offer a comprehensive portfolio of drug candidate evaluation services including DMPK, Safety and Toxicology, and Bioanalytical related services.
Our portfolio of Product Development and CMC services spans drug discovery to the post approval phase, including lead compound quantification and analytical testing.
With Over 20 years of experience in the execution of comprehensive Phase I-IIa studies, Frontage Clinical Services has completed more than 250 studies.
At Frontage, we provide clients with integrated research, analytical and development services throughout the drug discovery and development process.
2021, marks the 20th anniversary of Frontage Laboratories. We are focused on helping our client’s to address their most significant...
COVID-19 Testing Information Welcome to your COVID-19 Testing Information Page. We are just 45 minutes away from Philadelphia International Airport...
Frontage combines our in-house clinical and DMPK expertise to provide our clients a comprehensive approach from initial planning for their hAME study through final study report. Frontage Clinical Services Approach: Purpose built clinical facility with a dedicated unit to conduct hAME studies. Expert hAME study protocol development/review, along with data management and biometrics support services. Rapid recruitment from a large database of healthy volunteer subjects, and study conduct by highly skilled and experienced research team. Dedicated, restricted access ward to accommodate up to 8 subjects in our 160-bed Phase 1 unit. On-site compounding pharmacy for dose preparation. Experienced nuclear pharmacist to prepare doses on site for oral or injection administration. Collection and processing of subject blood and excreta. Seamless integration with Frontage DMPK for sample analysis and real-time radioactivity counting that allows for timely subject release. Frontage Labs Highly Experienced DMPK Team Approach: Following QWBA, a radiation dosimetry report that is based on current regulatory recommendations is provided prior to hAME study conduct. A detailed analytical protocol is provided for the analysis of samples to support the hAME study. Daily reporting of mass balance data to demonstrate recovery and excretion pathways of administered radioactivity. Furthermore, daily mass balance data to ensure the timely release of subjects who meet the discharge criteria. DMPK-to-Clinical transition of information within Frontage fosters minimal delays in reporting data and enhances timeline efficiencies. Metabolite identification, characterization and profiling of samples by industry’s leading experts equipped with the state-of-the-art instrumentation. Sample Timeline for hAME Study Frontage hAME Team • Expert staff with an average of 25 years’ experience in QWBA, dosimetry, hAME, and early phase clinical studies. • QA staff to support all aspects of hAME studies. • A science-driven team of scientists to provide scientific input and deliver high quality data in a timely manner. • Proven history of flexibility, focus on communication, and successful execution of all pre-clinical and clinical studies.
We know that to attract the best candidates we have to provide a stimulating and challenging work environment that gives our employees the opportunity to meet their career goals. We also recognize the need to offer a competitive benefits package for our employees and their families.Learn More